Project Title: Lenabasum MOA

Client: Corbus Pharmaceuticals Holdings, Inc.

DESCRIPTION

Chronic inflammation is a harmful process that can lead to fibrosis, organ damage, and even loss of organ function. It occurs when the immune system is activated and remains active for a prolonged period of time. Research has shown that targeting of Cannabinoid Type II receptors on immune cells can reduce inflammation and limit fibrosis.

Lenabasum is a small molecule that selectively activates CB2 receptors. Taken orally, this novel drug activates the resolution of inflammation and limits fibrosis, without suppressing the immune system.

Award of Excellence

2019 Videographer Awards
“Anabasum: Mechanism of Action”, Video Production – Animation

Award of Excellence

2018 AMI Conference
Didactic/Commercial

SEE ALSO

CRSPR Cas-9

UroAmplitude